We read with great interest the study by Levenick et al1 on the utility of rectal indomethacin in consecutive patients to prevent post-ERCP pancreatitis (PEP). We congratulate the authors on their publication, but query some additional limitations that may influence the generalizability of this study especially in patients at high risk for PEP.